Shots:
- MEDIPOST has reported the P-III trial data assessing Cartistem (n=59) vs hyaluronic acid (n=61) in 130 knee osteoarthritis pts over a 52wk. follow-up period across 13 Japanese sites
- Trial met both co-1EPs of WOMAC knee pain & function scores, and ICRS cartilage repair grading. Improvements were also observed across all 2EPs, incl. VAS pain scores, IKDC & KOOS knee function assessments, plus WOMAC subscales for pain, function, & stiffness
- WOMAC & 100 mm VAS endpoints, aligned with the ongoing US P-III trial, showed superiority over active control, while the company plans a BLA filing in Japan in H2’26, targeting end-2027 approval
Ref: PRnewswire | Image: MEDIPOST | Press Release
Related News: Biogen Reports P-II (CELIA) Trial Results on Diranersen in Early Alzheimer’s Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
